The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Multifactorial Intervention and Cardiovascular Disease in Patients with Type 2 Diabetes
Open accessAbstract
BACKGROUND: Cardiovascular morbidity is a major burden in patients with type 2 diabetes. In the Steno-2 Study, we compared the effect of a targeted, intensified, multifactorial intervention with that of conventional treatment on modifiable risk factors for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. METHODS: The primary end point of this open, parallel trial was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, revascularization, and amputation. Eighty patients were randomly assigned to receive conventional treatment in accordance with national guidelines and 80 to receive intensive treatment, with a stepwise implementation of behavior modification and pharmacologic therapy that targeted hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention of cardiovascular disease with aspirin. RESULTS: The mean age of the patients was 55.1 years, and the mean follow-up was 7.8 years. The decline in glycosylated hemoglobin values, systolic and diastolic blood pressure, serum cholesterol and triglyceride levels measured after an overnight fast, and urinary albumin excretion rate were all significantly greater in the intensive-therapy group than in the conventional-therapy group. Patients receiving intensive therapy also had a significantly lower risk of cardiovascular disease (hazard ratio, 0.47; 95 percent confidence interval, 0.24 to 0.73), nephropathy (hazard ratio, 0.39; 95 percent confidence interval, 0.17 to 0.87), retinopathy (hazard ratio, 0.42; 95 percent confidence interval, 0.21 to 0.86), and autonomic neuropathy (hazard ratio, 0.37; 95 percent confidence interval, 0.18 to 0.79). CONCLUSIONS: A target-driven, long-term, intensified intervention aimed at multiple risk factors in patients with type 2 diabetes and microalbuminuria reduces the risk of cardiovascular and microvascular events by about 50 percent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although HRV testing is largely confined to the research setting, the CV reflex tests that assess changes in HRV during standardized clinical challenges such as deep breathing, Valsalva maneuver and supine-to-standing position remain the gold standard tests and are available for clinical care as well.547,614,626”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [626]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to traditional risk factors, hyperglycemia, hyperinsulinemia, and oxidative stress contribute to endothelial damage, leading to poor arterial function and greater susceptibility to atherogenesis ( 45 , 82 , 289 ).”
From Exercise and Type 2 Diabetes (2010) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, studies in people with T2D and early CKD demonstrated the long-term bene fi t of multifactorial intervention on the development of microvascular and macrovascular complications and mortality.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (222,227,228).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [227]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Results from several randomized controlled trials revealed that more intensive treatment of risk factors in people with increased levels of natriuretic peptides reduces the risk for symptomatic heart failure, heart failure hospitalization, and newly diagnosed left ventricular dysfunction (211,216,217).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [216]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people who already have diabetes, lifestyle modification and pharmacological treatment, as well as blood pressure and cholesterol control, can delay progression to complications and reduce mortality, or even help with remission, especially if started early.1,2,58–62”
From Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants (2024) · cites this paper as [58]
Experimental — accuracy not yet measuredIn the citing paper
“The benefit of the intensive multifactorial intervention was demonstrated by a significant reduction in the incidence of microvascular complications after 4 years, and a significant 53% risk reduction in macrovascular complications after 8 years.455”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [455]
In the citing paper
“Angiotensin-converting enzyme inhibitors812), angiotensin Ⅱ receptor blockers813), and calcium channel antagonists814) have been reported to be effective for preventing cardiovascular events in patients with DM.”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [813]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 4,803
Stamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
Research works printed but not linked: 2
- 10.1001/jama.241.19.2035 · DOI · Paper page
- 10.1001/archinte.151.6.1141 · DOI
Cited by
Sorted by citations
Items 901–1,000 of 1,025
Nicorandil as a novel therapy for advanced diabetic nephropathy in the eNOS-deficient mouse
Tanabe, K., Lanaspa, M. A., Kitagawa, W., Rivard, C. J., Miyazaki, M., Klawitter, J., Schreiner, G. F., Saleem, M. A., Mathieson, P. W., Makino, H., et al. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00596.2011 · Cited by 55
Turner, J., Larsen, M. E., Tarassenko, L., Neil, A., & Farmer, A. A. (2009) · Journal of Innovation in Health Informatics · doi:10.14236/jhi.v17i1.714 · Cited by 55
Metabolic Issues in Patients with Severe Mental Illness
Citrome, L., Blonde, L., & Damatarca, C. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000167621.49292.11 · Cited by 55
Mynarski, W., Psurek, A., Borek, Z., Rozpara, M., Grabara, M., & Strojek, K. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.024 · Cited by 55
Identification of myocardial ischemia in the diabetic patient Joint ALFEDIAM and SFC recommendations
Puel, J., Valensi, P. E., Vanzetto, G., Lassmann-Vague, V., Monin, J.-L., Moulin, P., Ziccarelli, C., Mayaudon, H., Ovize, M., Bernard, S. A., et al. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(04)72800-1 · Cited by 55
Therapeutic Goal Attainment in Patients With Hypertension and Dyslipidemia
Johnson, M. L., Pietz, K., Battleman, D. S., & Beyth, R. J. (2005) · Medical Care · doi:10.1097/01.mlr.0000188982.25397.37 · Cited by 55
Yuyun, M. F., Khaw, K., Luben, R., Welch, A. A., Bingham, S. A., Day, N., & Wareham, N. J. (2004) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000133070.75016.1d · Cited by 55
What determines the cost-effectiveness of diabetes screening?
Glümer, C., Yuyun, M., Griffin, S., Farewell, D., Spiegelhalter, D., Kinmonth, A. L., & Wareham, N. J. (2006) · Diabetologia · doi:10.1007/s00125-006-0248-x · Cited by 54
Sheikh, M. H., Errede, M., d’Amati, A., Khan, N. Q., Fanti, S., Loiola, R. A., McArthur, S., Purvis, G. S. D., O’Riordan, C. E., Ferorelli, D., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202101297r · Cited by 56
Potential Benefits of Antioxidant Phytochemicals in Type 2 Diabetes
Arabshomali, A., Bazzazzadehgan, S., Mahdi, F., & Shariat‐Madar, Z. (2023) · Molecules · doi:10.3390/molecules28207209 · Cited by 56
GLP-1 Agonists and Dipeptidyl-Peptidase IV Inhibitors
Gallwitz, B. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-17214-4_3 · Cited by 56
CHO, E. J., Park, H. C., Yoon, H. B., Ju, K. D., Kim, H. J., Oh, Y. K., Yang, J., Hwang, Y., Ahn, C., & OH, K. (2012) · Nephrology · doi:10.1111/j.1440-1797.2012.01598.x · Cited by 54
Receipt of Diabetes Preventive Services Differs by Insurance Status at Visit
Bailey, S. R., OʼMalley, J. P., Gold, R. B., Heintzman, J., Marino, M., & DeVoe, J. E. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2014.08.035 · Cited by 59
Sitagliptin: Anti-platelet effect in diabetes and healthy volunteers
Gupta, A. K., Verma, A. K., Kailashiya, J., Singh, S. K., & Kumar, N. (2012) · Platelets · doi:10.3109/09537104.2012.721907 · Cited by 54
Si, D., Bailie, R. S., & Weeramanthri, T. S. (2008) · Primary Health Care Research & Development · doi:10.1017/s1463423607000473 · Cited by 54
ABC control of diabetes: Survey data from National Diabetes Health Promotion Centers in Taiwan
Yu, N.-C., Su, H.-Y., Tsai, S., Lin, B. J., Shiu, R.-S., Hsieh, Y.-C., & Sheu, W. H. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.02.020 · Cited by 55
Welschen, L. M. C., van Oppen, P., Bot, S. D. M., Kostense, P. J., Dekker, J. M., & Nijpels, G. (2012) · Journal of Behavioral Medicine · doi:10.1007/s10865-012-9451-z · Cited by 54
Simpson, S. H., Lier, D. A., Majumdar, S. R., Tsuyuki, R. T., Lewanczuk, R. Z., Spooner, R., & Johnson, J. A. (2015) · Diabetic Medicine · doi:10.1111/dme.12692 · Cited by 54
Tanaka, S., Tanaka, S., Iimuro, S., Yamashita, H., Katayama, S., Ohashi, Y., Akanuma, Y., Yamada, N., & Sone, H. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt057 · Cited by 54
Xu, W., Zhu, Y., Yang, X., Deng, H., Yan, J., Lin, S., Yang, H.-Z., Chen, H., & Weng, J. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.078 · Cited by 54
Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function
Jørgensen, P. G., Jensen, M. T., Møgelvang, R., Fritz‐Hansen, T., Galatius, S., Biering‐Sørensen, T., Storgaard, H., Vilsbøll, T., Rossing, P. R., & Jensen, J. S. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.083 · Cited by 56
Jensen, T. M., Vistisen, D., Fleming, T. H., Nawroth, P. P., Rossing, P. R., Jørgensen, M. E., Lauritzen, T., Sandbæk, A., & Witte, D. R. (2016) · Diabetic Medicine · doi:10.1111/dme.13201 · Cited by 54
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.745 · Cited by 54
Perriello, G., Pampanelli, S., Porcellati, F., Avogaro, A., Bosi, E., Petrella, G., Squatrito, S., Furneri, S., Marra, G., Vitali, L., et al. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01473.x · Cited by 54
Danchin, N., Cambou, J., Hanania, G., Kadri, Z., Genès, N., Lablanche, J., Blanchard, D., Vaur, L., Clerson, P., & Guéret, P. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.01.058 · Cited by 54
The Use of Vitamin E in Type 2 Diabetes Mellitus
Fardoun, R. Z. (2007) · Clinical and Experimental Hypertension · doi:10.1080/10641960701361601 · Cited by 54
Maddigan, S. L., Majumdar, S. R., Guirguis, L. M., Lewanczuk, R. Z., Lee, T. K., Toth, E. L., & Johnson, J. A. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1306 · Cited by 54
Cardiovascular autonomic neuropathy: A silent killer with long reach
Ang, L., Dillon, B., Mizokami-Stout, K., & Pop-Busui, R. (2020) · Autonomic Neuroscience · doi:10.1016/j.autneu.2020.102646 · Cited by 53
Brown, S. E. S., Meltzer, D. O., Chin, M. H., & Huang, E. S. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2008.01757.x · Cited by 53
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
Avogaro, A., Fadini, G. P., Sesti, G., Bonora, E., & Prato, S. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0431-4 · Cited by 53
The conundrum of diabetic neuropathies—Past, present, and future
Ang, L. P., Mizokami‐Stout, K., Eid, S., Elafros, M. A., Callaghan, B. C., Feldman, E. L., & Pop‐Busui, R. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108334 · Cited by 54
Metabolic syndrome in subjects with type-2 diabetes mellitus.
Alebiosu, C. O., & Odusan, B. (2004) · PubMed Central · Cited by 53
Bile Acid Sequestrants: Glucose-Lowering Mechanisms and Efficacy in Type 2 Diabetes
Hansen, M., Sonne, D. P., & Knop, F. K. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0482-4 · Cited by 55
Abe, M., & Matsumoto, K. (2008) · Nature Reviews Nephrology · doi:10.1038/ncpneph0881 · Cited by 53
B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetes
Rana, B. S., Davies, J. I., Band, M. M., Pringle, S. D., Morris, A., & Struthers, A. D. (2005) · Heart · doi:10.1136/hrt.2005.071423 · Cited by 53
PROactive: time for a critical appraisal
Betteridge, D. J., DeFronzo, R. A., & CHILTON, R. J. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn114 · Cited by 53
Need for better diabetes treatment for improved renal outcome
Rossing, P. R., & de Zeeuw, D. (2011) · Kidney International · doi:10.1038/ki.2010.513 · Cited by 54
Verhoeven, V., der Auwera, A. V., Gaal, L. V., Remmen, R., Apers, S., Stalpaert, M., Wens, J., & Hermans, N. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0576-9 · Cited by 53
Willis, W. D., Diago, J. I., Madec-Hily, A., & Aslam, A. (2013) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.12.80 · Cited by 53
Heymann, A. D., Chodick, G., Halkin, H., Karasik, A., Shalev, V., Shemer, J., & Kokia, E. S. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.07.002 · Cited by 53
Goderis, G., Borgermans, L. A. D., Mathieu, C., Broeke, C. V. D., Hannes, K., Heyrman, J., & Grol, R. P. T. M. (2009) · Implementation Science · doi:10.1186/1748-5908-4-41 · Cited by 55
Tovar, E. G., Rayens, M. K., Clark, M. C., & Nguyen, H. (2010) · Journal of Advanced Nursing · doi:10.1111/j.1365-2648.2010.05443.x · Cited by 53
Greer, R. C., Powe, N. R., Jaar, B. G., Troll, M. U., & Boulware, L. E. (2011) · BMC Nephrology · doi:10.1186/1471-2369-12-1 · Cited by 53
Dudl, R. J., Wang, M. C., Wong, M., & Bellows, J. (2009) · PubMed · Cited by 53
Flack, J. M., Victor, R. G., Watson, K. E., Ferdinand, K. C., Saunders, E., Tarasenko, L. C., Jamieson, M. J., Shi, H. H., & Bruschi, P. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.1.35 · Cited by 53
Preventive Cardiology as a Subspecialty of Cardiovascular Medicine
Shapiro, M. D., Maron, D. J., Morris, P. B., Kosiborod, M., Sandesara, P. B., Virani, S. S., Khera, A., Ballantyne, C. M., Baum, S. J., Sperling, L. S., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1016 · Cited by 55
Diabetes mellitus in pregnancy
Galerneau, F., & Inzucchi, S. E. (2004) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2004.09.002 · Cited by 53
Matrix Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinase-1 and -2 in Type 2 Diabetes
Tayebjee, M. H., Lim, H. S., MacFadyen, R. J., & Lip, G. Y. H. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2049 · Cited by 53
Ali, M. K. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch5 · Cited by 53
Severity of periodontitis and metabolic syndrome: is there an association?
Gomes‐Filho, I. S., das Mercês, M. C., de Santana Passos‐Soares, J., Seixas da Cruz, S., Teixeira Ladeia, A. M., Trindade, S. C., de Moraes Marcílio Cerqueira, E., Freitas Coelho, J. M., Marques Monteiro, F. M., Barreto, M. L., et al. (2016) · Journal of Periodontology · doi:10.1902/jop.2015.150367 · Cited by 52
Muller, N., Heller, T., Freitag, M., Gerste, B., Haupt, C. M., Wolf, G., & Müller, U. (2015) · Diabetic Medicine · doi:10.1111/dme.12747 · Cited by 52
Overall Mortality in Diabetes Mellitus: Where Do We Stand Today?
DAILEY, G. E. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0019 · Cited by 52
Predictors of Adherence With Antihypertensive and Lipid-Lowering Therapy
Chapman, R. H., Benner, J. S., & Petrilla, A. A. (2005) · ACC Current Journal Review · doi:10.1016/j.accreview.2005.08.206 · Cited by 52
Beever, R. (2010) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2009.0358 · Cited by 52
Gentile, S., Agrusta, M., Guarino, G., Carbone, L., Cavallaro, V., Carucci, I., & Strollo, F. (2010) · Acta Diabetologica · doi:10.1007/s00592-009-0172-x · Cited by 52
Sundquist, K., Chaikiat, Å., León, V. R., Johansson, S., & Sundquist, J. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1161 · Cited by 52
Mogensen, U. M., Andersson, C., Fosbøl, E. L., Schramm, T. K., Vaag, A. A., Scheller, N. M., Torp-Pedersen, C. T., Gislason, G., & Køber, L. (2014) · Diabetologia · doi:10.1007/s00125-014-3372-z · Cited by 52
Sacre, J. W., Jellis, C. L., Jenkins, C., Haluska, B. A., Baumert, M., Coombes, J. S., & Marwick, T. H. (2014) · Metabolism · doi:10.1016/j.metabol.2014.05.007 · Cited by 52
Pulse-Wave-Pattern Classification with a Convolutional Neural Network
Li, G., Watanabe, K., Anzai, H., Song, X., Qiao, A., & Ohta, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-51334-2 · Cited by 54
Short-term very low calory diet reduces oxidative stress in obese type 2 diabetic patients
Škrha, J., Kunešová, M., Hilgertová, J., Weiserová, H., Křížová, J., & Kotrlikova, E. (2005) · Physiological Research · doi:10.33549/physiolres.930584 · Cited by 52
Fabry disease: diagnosis and management, with emphasis on the renal manifestations
Warnock, D. G. (2005) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200503000-00002 · Cited by 52
Norgaard, M. L., Andersen, S. S., Schramm, T. K., Folke, F., Jørgensen, C. H., Hansen, M. L., Andersson, C., Bretler, D., Vaag, A. A., Køber, L., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1783-z · Cited by 52
Metabolic Effects of ??-Adrenoceptor Antagonists with Special Emphasis on Carvedilol
Kveiborg, B., Christiansen, B., Major‐Pedersen, A., & Torp-Pedersen, C. T. (2006) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200606040-00001 · Cited by 52
Self-efficacy in patients with clinical manifestations of vascular diseases
Sol, B. G. M., van der Graaf, Y., van der Bijl, J. J., Goessens, N. B. G., & Visseren, F. L. J. (2005) · Patient Education and Counseling · doi:10.1016/j.pec.2005.05.011 · Cited by 52
van Zuilen, A. D., Wetzels, J. F. M., Bots, M. L., & Blankestijn, P. J. (2008) · Journal of Nephrology · doi:10.1093/joneph/21.3.261 · Cited by 52
Long-term, cause-specific mortality after myocardial infarction in diabetes
Timmer, J. R. (2004) · European Heart Journal · doi:10.1016/j.ehj.2004.04.001 · Cited by 52
de la Hera, J. M., Delgado, E., Hernández, E., Garcı́a-Ruiz, J. M., Vegas, J. M., y, P. A., Lozano, Í., Villa, R. B., Hevia, S., Martin, J. S., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp278 · Cited by 52
Hospitalizations, Nursing Home Admissions, and Deaths Attributable to Diabetes
Russell, L. B., Valiyeva, E., Roman, S. H., POGACH, L. M., Suh, D., & Safford, M. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1611 · Cited by 52
Reducing Cardiovascular Risk in Type 2 Diabetes
Solomon, C. G. (2003) · New England Journal of Medicine · doi:10.1056/nejme020172 · Cited by 52
Groop, P., Prato, S. D., Taskinen, M., Owens, D. R., Gong, Y., Crowe, S., Patel, S., von Eynatten, M., & Woerle, H. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12281 · Cited by 51
Wang, B., Fu, Y., Tan, X. W., Wang, N., Qi, L., & Lu, Y. (2024) · BMC Medicine · doi:10.1186/s12916-024-03343-w · Cited by 59
Multidrug Treatment of Type 2 Diabetes
Miccoli, R., Penno, G., & Prato, S. D. (2011) · Diabetes Care · doi:10.2337/dc11-s235 · Cited by 52
Raimundo, M. R., & Lopes, J. A. (2011) · Cardiology Research and Practice · doi:10.4061/2011/747861 · Cited by 54
Marso, S. P., Kennedy, K. F., House, J. A., & McGuire, D. K. (2009) · Diabetes and Vascular Disease Research · doi:10.1177/1479164109353367 · Cited by 51
Melmer, A., & Laimer, M. W. (2016) · Endocrine development · doi:10.1159/000439364 · Cited by 53
Cooper, A. R., Tibbitts, B., England, C. Y., Procter, D., Searle, A., Sebire, S. J., Ranger, E., & Page, A. S. (2018) · Diabetic Medicine · doi:10.1111/dme.13664 · Cited by 51
Börschel, C. S., & Schnabel, R. B. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.11.123 · Cited by 52
Uric Acid, Microalbuminuria and Cardiovascular Events in High-Risk Patients
Short, R., Johnson, R. J., & Tuttle, K. R. (2005) · American Journal of Nephrology · doi:10.1159/000084073 · Cited by 51
Improving Diabetes Care by Combating Clinical Inertia
O’Connor, P. J. (2005) · Health Services Research · doi:10.1111/j.1475-6773.2005.00437.x · Cited by 51
Thulé, P. M., Campbell, A. G., Kleinhenz, D. J., Olson, D. E., Boutwell, J., Sutliff, R. L., & Hart, C. M. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00134.2005 · Cited by 51
Daly, C. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl005 · Cited by 51
Lopes, A. A. (2004) · Advances in Renal Replacement Therapy · doi:10.1053/j.arrt.2003.10.006 · Cited by 51
Mohan, V., Shanthirani, C. S., Deepa, M., Deepa, R., Ranjit Unnikrishnan, I., & Datta, M. (2006) · PubMed · Cited by 51
Wilson, C., Gilliland, S. S., Cullen, T., MOORE, K. R., Roubideaux, Y. D., Valdez, L., Vanderwagen, W. C., & Acton, K. J. (2005) · American Journal of Public Health · doi:10.2105/ajph.2004.053710 · Cited by 51
Diabetes and Cardiovascular Disease Prevention in Older Adults
Cigolle, C. T., Blaum, C. S., & Halter, J. B. (2009) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.09.001 · Cited by 50
Kim, S. H., Lee, S. Y., Kim, C. W., Suh, Y. J., Hong, S., Ahn, S. H., Seo, D. H., Nam, M., Chon, S., Woo, J., et al. (2018) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.0102 · Cited by 50
New Insights into Treating Early and Advanced Stage Diabetic Retinopathy
Simó, R., & Hernández, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158513 · Cited by 54
Cardoso, C. R. L., Moran, C. B. M., Marinho, F. D. S., Ferreira, M. T., & Salles, G. F. (2015) · Diabetologia · doi:10.1007/s00125-015-3658-9 · Cited by 50
Independent Association of HbA1c and Incident Cardiovascular Disease in People Without Diabetes
Adams, R., Appleton, S., Hill, C. L., WILSON, D. H., Taylor, A. W., Chittleborough, C., Gill, T. K., & Ruffin, R. E. (2009) · Obesity · doi:10.1038/oby.2008.592 · Cited by 50
Ishimura, E., Okuno, S., Kono, K., Fujino-Kato, Y., Maeno, Y., Kagitani, S., Tsuboniwa, N., Nagasue, K., Maekawa, K., Yamakawa, T., et al. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.11.038 · Cited by 50
Current challenges in diabetes management
Blonde, L. (2005) · Clinical cornerstone · doi:10.1016/s1098-3597(05)80084-5 · Cited by 50
Mehlsen, J., Erlandsen, M., Poulsen, P. L., & Bek, T. (2009) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01742.x · Cited by 50
Rahman, M., Simmons, R. K., Hennings, S., Wareham, N. J., & Griffin, S. J. (2012) · Diabetologia · doi:10.1007/s00125-011-2441-9 · Cited by 50
Netto, A. P., Rodbard, D., & Zanella, M. T. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0054 · Cited by 51
Franch‐Nadal, J., Mata‐Cases, M., Vinagre, I., Patitucci-Gómez, F., Hermosilla, E., Casellas, A., Bolívar, B., & Mauricio, D. (2014) · International Journal of Endocrinology · doi:10.1155/2014/131709 · Cited by 50
Long, G. H., Cooper, A., Wareham, N. J., Griffin, S. J., & Simmons, R. K. (2014) · Diabetes Care · doi:10.2337/dc13-1731 · Cited by 51
Berardis, G. D., Pellegrini, F., Franciosi, M., Belfiglio, M., Nardo, B. D., Greenfield, S., Kaplan, S. H., Rossi, M. C., Sacco, M. C., Tognoni, G., et al. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2006.04.009 · Cited by 50
Bhattacharyya, O. K., Shah, B. R., & Booth, G. L. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080554 · Cited by 53
Bertoccini, L., & Baroni, M. G. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_494 · Cited by 49
Araki, A., Iimuro, S., Sakurai, T., Umegaki, H., Iijima, K., Nakano, H., Oba, K., Yokono, K., Sone, H., Yamada, N., et al. (2012) · Geriatrics & Gerontology International · doi:10.1111/j.1447-0594.2011.00809.x · Cited by 49
Metadata
- Authors
- Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- Herlev Hospital (DK)
- Roskilde Sygehus (DK)
- Aarhus University (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-01-30
- Volume
- 348
- Issue
- 5
- Pages
- 383-393
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2139634859
- Cited by
- 4,378
- References
- 26
- Citations by year
- 2026: 47 · 2025: 71 · 2024: 108 · 2023: 110 · 2022: 102 · 2021: 137 · 2020: 142 · 2019: 133 · 2018: 171 · 2017: 143 · 2016: 158 · 2015: 169 · 2014: 198 · 2013: 184 · 2012: 235
- FWCI
- 178.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, cardiovascular disease, multifactorial intervention, microalbuminuria, tight glycemic control, hyperglycemia, hypertension, dyslipidemia, aspirin, myocardial infarction, stroke, kidney disease, retinopathy, autonomic neuropathy
- MeSH terms
- Amputation, Surgical, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Hypolipidemic Agents, Cardiovascular Diseases, Combined Modality Therapy, Diabetes Mellitus, Diabetes Mellitus, Type 2, Female, Humans, Hyperlipidemias, Hypertension, Hypoglycemic Agents, Male, Middle Aged, Myocardial Infarction, Obesity, Risk Factors, Vitamins, Exercise, Smoking Cessation, Diet, Fat-Restricted, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
